217476-14-7

Upstream product

• 1073-06-9 3-fluorobromobenzene 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 680596-79-6 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane 
• 768-35-4 3-fluorophenylboronic acid 

Downstream Products

• 1402080-51-6 5-(3-fluorophenyl)oxepan-2-one 
• 40503-87-5 4-(3-fluorophenyl)cyclohexan-1-one 
• 206533-08-6 4-(4-propylidenecyclohexyl)-2-fluoro-1-iodobenzene 
• 206533-06-4 4-(3-fluoro-4-iodophenyl)cyclohexanone 
• 206533-10-0 2-Fluoro-4-(4-fluoro-4-propyl-cyclohexyl)-1-iodo-benzene 
• 206533-05-3 8-(3-fluoro-4-iodophenyl)-1,4-dioxaspiro[4.5]decane 

Relevant academic research and scientific papers

HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS

The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS

The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF

Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist act

Enantioselective baeyer-villiger oxidation: Desymmetrization of meso cyclic ketones and kinetic resolution of racemic 2-arylcyclohexanones

Catalytic enantioselective Baeyer-Villiger (BV) oxidations of racemic and meso cyclic ketones were achieved in the presence of chiral N,N'-dioxide-Sc III complex catalysts. The BV oxidations of prochiral cyclohexanones and cyclobutanones afforded series of optically active μ- and γ-lactones, respectively, in up to 99% yield and 95% ee. Meanwhile, the kinetic resolution of racemic 2-arylcyclohexanones was also realized via an abnormal BV oxidation. Enantioenriched 3-aryloxepan-2-ones, whose formation is counter to the migratory aptitude, were obtained preferentially. Both the lactones and the unreacted ketones were obtained with high ee values.

Enantioselective baeyer-villiger oxidation: Desymmetrization of meso cyclic ketones and kinetic resolution of racemic 2-arylcyclohexanones

Catalytic enantioselective Baeyer-Villiger (BV) oxidations of racemic and meso cyclic ketones were achieved in the presence of chiral N,N'-dioxide-Sc III complex catalysts. The BV oxidations of prochiral cyclohexanones and cyclobutanones afforded series of optically active μ- and γ-lactones, respectively, in up to 99% yield and 95% ee. Meanwhile, the kinetic resolution of racemic 2-arylcyclohexanones was also realized via an abnormal BV oxidation. Enantioenriched 3-aryloxepan-2-ones, whose formation is counter to the migratory aptitude, were obtained preferentially. Both the lactones and the unreacted ketones were obtained with high ee values.

LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT

The invention provides a liquid crystal compound having stability to heat, light and so forth, a wide temperature range of the nematic phase, a small viscosity, a suitable optical anisotropy, a suitable dielectric anisotropy and an excellent compatibility

TETRA- OR PENTA-CYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT

The invention provides a liquid crystal compound having stability to heat, light and so forth, a wide temperature range of a nematic phase, a small viscosity, a suitable optical anisotropy, and a suitable elastic constant K33, and further having a suitable and negative dielectric anisotropy and an excellent compatibility with other liquid crystal compounds, and a liquid crystal composition having stability to heat, light and so forth, a low viscosity, a large optical anisotropy, a suitable and negative dielectric anisotropy, and a suitable elastic constant K33, a low threshold voltage, a high maximum temperature (phase-transition temperature on a nematic phase-isotropic phase) of a nematic phase, and a low minimum temperature of the nematic phase. The liquid crystal compound which has a specific structure having fluorine at a lateral position and also having phenylene in which hydrogen on the benzene ring is replaced by fluorine, and a liquid crystal composition containing the compound are prepared.

Fluorocyclohexane derivatives, and liquid-crystalline medium

The invention relates to fluorocyclohexane derivatives of the formula I in which R1, Z1, Z2, L1, L2, L3 and X are as defined as below: X is alkyl or alkoxy having 1 to 10 carbon atoms which is unsubstituted or substituted by halogen, alkenyl or alkenyloxy having 2 to 10 carbon atoms which is unsubstituted or substituted by -CN, -CF3 or -F, or is -CN, -F, -OCHF2, -OCF3, -OCHFCF3 or -OCF2CF3, L1, L2 and L3 are each, independently of one another, H or F, R1 is H, an alkyl or alkenyl radical having 1-12 carbon atoms which is unsubstituted, monosubstituted by CN or CF3 or substituted by halogen, where one or more non-adjacent CH2 groups in these radicals may also, in each case independently of one another, be replaced by -O-, -S-, -CO-, -+566 -, -CO-O-, -O-CO- or -O-CO-O-, Z1 and Z2 are each, independently of one another, -CO-O-, -O-CO-, -CH2O-, -O-, -O-CH2-, -CH2CH2-, -CH=CH-, -C 3BOND C- or a single bond, with the proviso that compounds of the formula I in which L1 is H and Z2 is simultaneously a single bond are excluded.